Pernix Therapeutics Holdings Inc., of Morristown, N.J., said it signed an agreement with Glaxosmithkline plc, of London, to acquire the U.S. rights to Treximet (sumatriptan/naproxen sodium) for the acute treatment of migraine attacks with or without aura in adults.